Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Single investor buys 16mm common shares of Cell Therapeutics

Executive Summary

On the heels of a $20mm preferred stock placement completed in April, cancer company Cell Therapeutics netted $19mm through the sale this month of 16mm common shares at $1.25 each (an 89% premium) to Iroquois Master Fund. The sole investor also received five-year warrants to purchase up to 4.8mm more shares at an exercise price of $1.40. Rodman & Renshaw was the placement agent.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Biotech
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register